Literature DB >> 24277244

Drug concentration, binding, and effect in vivo.

N H Holford1.   

Abstract

It is an axiom of pharmacodynamics that drug effects are determined by drug concentration at the site of action. The link between concentration and effect can often be described by empirical models, but the ability to measure binding to the target tissue permits a more detailed description. The action and interaction of drugs at identifiable receptor sites can then be predicted from a knowledge of their binding properties and the law of mass action. The time course of drug effect is determined not only by drug disposition reflected in the blood circulation but also by the equilibration rate between blood and the effect site, and the steps linking the direct actions of the drug to their expression as an observable drug effect. Models encompassing these phenomena have been developed and have been applied in many situations to describe the kinetics of pharmacological response.

Year:  1984        PMID: 24277244     DOI: 10.1023/A:1016367701698

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.

Authors:  R A O'Reilly; P M Aggeler
Journal:  Circulation       Date:  1968-07       Impact factor: 29.690

Review 2.  Kinetics of pharmacologic response.

Authors:  N H Holford; L B Sheiner
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

5.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

6.  Opiate receptor binding-effect relationship: sufentanil and etorphine produce analgesia at the mu-site with low fractional receptor occupancy.

Authors:  J S Rosenbaum; N H Holford; W Sadée
Journal:  Brain Res       Date:  1984-01-23       Impact factor: 3.252

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Buprenorphine: differential interaction with opiate receptor subtypes in vivo.

Authors:  W Sadée; J S Rosenbaum; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1982-10       Impact factor: 4.030

  8 in total
  5 in total

1.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

Review 2.  Kinetic-effect models and their applications.

Authors:  J Grevel
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

3.  Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone.

Authors:  R E Jonkers; M C Braat; R P Koopmans; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

5.  Pharmacokinetics and pharmacodynamics of thiazinamium in asthmatic patients.

Authors:  N H Holford; P Clements; P Collier; N G Orie; L E van Bork; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.